Notwithstanding, the BRAF V600E mutation is more common in pleomorphic xanthoastrocytoma (42/64–66%) and in 15/23 (65%) of pleomorphic xanthoastrocytoma with anaplasia, characterizing BRAF V600E as a valuable marker for gene panel diagnostics in all CNS tumors. This evidence concerns the gene BRAF and central nervous system neoplasm.